ECG abnormalities in HeFREF are widely described and guide medical and device therapy. However, many studies in HeFNEF do not report ECG characteristics other than heart rhythm. Hence, other than a high prevalence of atrial fibrillation, little is known about ECG features associated with HeFNEF. In recent years, attempts have been made to identify different phenotypic groups among patients with HeFNEF based on comorbidities, such as hypertension, obesity, or lung disease, in order to target therapeutic interventions and predict outcomes (Gorter et al., 2018; Shah et al., 2015) . ECG variables may provide an additional noninvasive tool to help identify distinct phenotypes with different trajectories.
| ME THODS

| Search strategy and selection criteria
We identified peer-reviewed studies published in English in patients with HeFNEF describing ECG variables other than heart rhythm alone. Participants included were men and women with a diagnosis of HeFNEF. We included the following types of studies performed in al., 2017) and the general population (Ho et al., 2013; Lee et al., 2009) ).
Two studies provided ECG characteristics specifically in patients with heart failure and mid-range ejection fraction 40%-49% (HeFmrEF) (Lund et al., 2013; Pascual-Figal et al., 2017) .
| Participants
A total of 32,006 participants with HeFNEF were included. The mean age was 74 years, and 56% were women. Participant comorbidities are summarized in Appendix II.
| Atrial fibrillation
In the studies we identified, the prevalence of atrial fibrillation or atrial flutter on ECG was 12%-46% (Adabag et al., 2014; Cenkerova et al., 2016; Donal et al., 2014; Ho et al., 2013; Khan et al., 2007; Lee et al., 2009; Masoudi et al., 2003; Nikolaidou et al., 2017; Olsson et al., 2006; Oskouie et al., 2017; Pascual-Figal et al., 2017; Peyster et al., 2004; Sanchis et al., 2015; Selvaraj et al., 2014; Senni et al., 1998; Shah et al., 2013; Yap et al., 2015) . The percentage of patients with a history of atrial fibrillation (where reported) was greater (Lee et al., 2009; Shah et al., 2013) . In the studies including patients with HeFREF, the prevalence of atrial fibrillation was lower (15%-36%)
in HeFREF than in HeFNEF (16%-46%) (Cenkerova et al., 2016; Hawkins et al., 2007; Nikolaidou et al., 2017; Park et al., 2013; Pascual-Figal et al., 2017; Peyster et al., 2004; Senni et al., 1998; Yap et al., 2015) . Only one study (of 2,258 patients admitted with heart failure) found a higher prevalence of atrial fibrillation in patients with reduced ejection fraction (26% vs. 20%) (Varadarajan & Pai, 2003) .
In the CHARM program, 7,599 patients with heart failure and NYHA class symptoms II-IV were randomized to candesartan or placebo and followed up for 38 months. 3,023 patients had HeFNEF (ejection fraction > 40%) and 478 (16%) of these had atrial fibrillation at baseline. The presence of atrial fibrillation at baseline was an independent risk factor for cardiovascular death or hospitalization for heart failure and all-cause mortality after adjusting for 32 covariates (Olsson et al., 2006) .
| P/PR duration
First-degree AV block (PR ≥ 200 ms) was present in 11%-21% of patients with HeFNEF (Donal et al., 2014; Khan et al., 2007; Nikolaidou et al., 2017) but was more common in patients with HeFREF (21%-26%) (Khan et al., 2007; Nikolaidou et al., 2017) .
In a prospective observational study of 539 patients admitted to hospital with clinical signs of heart failure and LVEF > 45%, 11% had 1st-degree heart block (Donal et al., 2014) . Higher degree 
| QRS
Left bundle branch block (LBBB) is present in up to 50% of patients with HeFREF(Danciu et al., 2006; Khan et al., 2007; Lund et al., 2013; Senni et al., 1998; Varadarajan & Pai, 2003) but only 0%-8% of patients with HeFNEF (Donal et al., 2014; Khan et al., 2007; Komajda et al., 2011; Lee et al., 2009; Masoudi et al., 2003; Menet et al., 2014; Peyster et al., 2004; Shah et al., 2013; Varadarajan & Pai, 2003) . Right bundle branch block (RBBB) is present in 5%-11% of patients with HeFREF (weighted average 7%) (Donal et al., 2014; Khan et al., 2007; Lee et al., 2009; Shah et al., 2013; Varadarajan & Pai, 2003) and in 6%-16% (weighted average 9%) of patients with HeFNEF (Figure 2a ) (Danciu et al., 2006; Donal et al., 2014; Hendry et al., 2016; Khan et al., 2007; Lee et al., 2009; Martinez Santos et al., 2016; Pascual-Figal et al., 2017; Selvaraj et al., 2014; Varadarajan & Pai, 2003) . RBBB is more common in patients with HeFNEF compared to HeFREF but without reaching statistical significance due to limited data available.
In an analysis of the CHARM trials, which included 3,023 patients with normal LVEF, any bundle branch block was present in 14% of patients with HeFNEF (and 30% of those with HeFREF) (Hawkins et al., 2007 (Donal et al., 2014) . A study of 3,696 ambulatory patients referred with suspected heart failure reported that 5% of 1,107 patients with HeFNEF had QRS ≥ 150 ms versus 18% of those with HeFREF (Nikolaidou et al., 2017) .
Increasing QRS duration (especially with LBBB morphology) is associated with increased mortality in HeFREF (Shamim et al., 1999) .
Conflicting results have been reported in patients with HeFNEF. In a study of 25,171 patients from the SwedeHF registry, increasing QRS duration was an independent risk factor for increasing all-cause mortality regardless of ejection fraction (Lund et al., 2013 ). An analysis of the TOPCAT trial showed that the risk of heart failure hospitalization was significantly higher in patients with HeFNEF and QRS ≥ 120 ms (Joseph et al., 2016) . Another study of 872 patients admitted to Michigan community hospitals with HeFNEF reported that QRS duration >120 ms on a predischarge ECG was an independent predictor of postdischarge death (Hummel et al., 2009 ).
Increasing QRS duration was an independent predictor of increasing 2-year cardiovascular mortality but not all-cause mortality in an Asian population with heart failure and ejection fraction >50% (Yap et al., 2015) . In a retrospective study of 108 patients admitted with HeFNEF, the presence of intraventricular conduction defects with QRS > 120 ms was associated with higher 180-day readmission and mortality rates (adjusted for age) compared to patients with narrower QRS (Danciu et al., 2006) .
In contrast, in the CHARM trials, the presence of bundle branch block increased the risk of the primary outcome of cardiovascular death or unplanned hospital admission for heart failure only in patients with HeFREF and not those with HeFNEF (Hawkins et al., 2007) . Similarly, in the REACH (Resource Utilization Among
Congestive Heart Failure) study of 3,471 patients with heart failure, 1,811 of whom had normal ejection fraction (LVEF > 45%), longer QRS duration was again only associated with worse survival in patients with HeFREF (Shenkman et al., 2002) .
In an observational study of 2,913 inpatients and outpatients with heart failure (Singaporean Asian patients from the SHOP cohort and Swedish patients in the SwedeHF Registry), longer QRS increased the composite risk of heart failure hospitalization or death in patients with HeFREF but not HeFNEF (Gijsberts et al., 2016) .
The difference between this report and the main SwedeHF registry (Lund et al., 2013) may reflect the fact that this study was designed to assess differences between Singaporean and Swedish cohorts.
Only the subset of patients from SwedeHF enrolled after 2009 was included (fewer than half of the total cohort), limiting statistical power, and the patients were followed for a much shorter period of time than in the main study.
In another observational study of 1,107 outpatients with HeFNEF followed up in the heart failure clinic for 3.7 years, QRS duration was associated with worse survival in univariable analysis but not when corrected for other variables (increasing log[NT-ProBNP], male sex, higher New York Heart Association class, age and a faster baseline heart rate) (Nikolaidou et al., 2017) . A report from the prospective Korean Acute Heart Failure Registry of patient admitted with heart failure showed that increasing QRS duration was not associated with HeFNEF (Park et al., 2013) .
We were able to pool outcome data associated with QRS duration in patients with HeFNEF from five studies (Figure 2b) ,
showing increased risk of death and heart failure admission when QRS ≥ 120 ms.
| Pathological Q waves
The prevalence of pathological Q waves in patients with HeFNEF was 11%-18% (Hendry et al., 2016; Khan et al., 2007; Shah et al., 2013) . In a study of 137 patients with a new diagnosis of heart failure, 15% of those with HeFNEF and 42% of those with HeFREF had evidence of previous myocardial infarction on ECG (history of coronary artery disease was present in 31% and 53%, respectively) (Senni et al., 1998) . In a study of 963 patients admitted to hospital with heart failure with LVEF ≥ 55%, 35% had evidence of acute myocardial infarction on ECG (compared with 60% of those with reduced ejection fraction) (Varadarajan & Pai, 2003) .
| Ventricular repolarization
Prolonged ventricular repolarization is associated with ventricular arrhythmias and increased risk of death (Moss, 1986) . Ventricular The JTc interval was longer in 1,107 patients with HeFNEF in an outpatients clinic compared to 1,155 patients in the same clinic found not to have heart failure (p = .01). However, abnormal duration of repolarization is uncommon in HeFNEF with 4.3% of patients with HeFNEF having severe JTc interval prolongation (>400 ms) compared to 4.7% of those without heart failure (Nikolaidou et al., 2017) . Similarly, the prevalence of JTc > 400 ms among 5,934 patients hospitalized with a suspected diagnosis of heart failure (excluding patients with ventricular pacing) was 3.1% in patients with no echocardiographic abnormality and 2.8% in those with echocardiographic evidence to support a diagnosis of HeFNEF (Khan et al., 2007) In these studies, the prevalence of JTc > 400 ms in patients with HeFREF was 4%-8% (Khan et al., 2007; Nikolaidou et al., 2017) .
In an observational study of 376 outpatients with HeFNEF, increasing frontal QRS-T angle was independently associated with higher B-type natriuretic peptide (BNP) level, worse left ventricular diastolic function and worse right ventricular systolic function.
Increasing QRS-T angle was also independently associated with an increase in the composite outcome of cardiovascular hospitalization even after adjusting for BNP (Selvaraj et al., 2014) .
| Left ventricular hypertrophy (LVH)
The prevalence of electrocardiographic evidence of LVH in studies of patients with HeFNEF ranges between 10% and 30% (Hendry et al., 2016; Khan et al., 2007; Komajda et al., 2011; Senni et al., 1998; Shah et al., 2013) . LVH may be more common in patients with
HeFREF (Hendry et al., 2016; Senni et al., 1998) . In six studies where information was available (Adabag et al., 2014; Hawkins et al., 2007; Komajda et al., 2011; Olsson et al., 2006; Shah et al., 2013) , criteria and Estes criteria (Romhilt & Estes, 1968 ).
| Multivariable models
A cross-sectional ECG study of 110 inpatients and outpatients with chronic heart failure in sinus rhythm at a single centre (50 with HeFNEF and EF > 40%) identified ECG variables that helped distinguish patients with HeFREF from those with HeFNEF. Those with HeFREF were more likely to have left atrial hypertrophy, QRS duration >100 ms, LBBB, absence of RBBB, ST-T segment changes, and QT interval prolongation. A model including all these variables separated the two conditions with 96% specificity and 76% sensitivity (Hendry et al., 2016) .
In 534 participants with new-onset heart failure from the Framingham heart study, those with HeFREF (LVEF ≤ 45%) were less likely to have atrial fibrillation and more likely to have LBBB and a faster heart rate at heart failure onset compared to patients with HeFNEF in multivariable analysis (Lee et al., 2009) .
In an analysis of the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE), four ECG variables (heart rate, LVH, LBBB, and atrial fibrillation/flutter) were included among 58 variables in a multivariable model for predicting morbidity and mortality. Only a faster heart rate was an independent predictor of all-cause mortality .
A study of 397 patients with HeFNEF previously hospitalized for heart failure used 67 variables (including six ECG variables) and modelbased clustering to describe distinct phenotypes among patients with
HeFNEF (Shah et al., 2015) . Phenogroup 1 included younger patients with fewer symptoms and lower BNP, as well as fewer ECG and echocardiographic abnormalities. Phenogroup 2 had the highest prevalence of obesity, diabetes, and COPD. Phenogroup 3 patients were older with higher BNP and higher prevalence of CKD and with the longest PR, QRS and QTc duration as well as greatest QRS-T angle compared to other groups. Phenogroup classification 1-3 was associated with a step-wise increase in the risk of heart failure hospitalization, cardiovascular hospitalization, or death even after adjusting for BNP.
| Risk of developing future heart failure
In a study of 6,340 participants from the Framingham Heart Study followed for 10 years, 196 developed HeFNEF and 261 HeFREF.
There were 14 predictors of incident heart failure. Higher body mass index, smoking, and atrial fibrillation predicted HeFNEF only, while male sex, higher cholesterol, higher heart rate, hypertension, cardiovascular disease, LVH, and LBBB predicted HeFREF (Ho et al., 2013) .
The MESA (Multi-Ethnic Study of Atherosclerosis) study followed 6,664 participants free from cardiovascular disease at baseline for a median of 12 years. Higher resting heart rate, abnormal P-wave axis, and abnormal QRS-T axis were independent predictors of future HeFNEF (O'Neal et al., 2017) .
| D ISCUSS I ON
We have found that atrial fibrillation is more common in patients with HeFNEF compared to those with HeFREF. RBBB is also more common in patients with HeFNEF. In contrast, long PR interval, LVH, Q waves, LBBB, and long JTc are more common in patients with
HeFREF. Therefore, a combination of variables, such as the presence of atrial fibrillation and the absence of LBBB, may help differentiate patients with HeFNEF compared to those with HeFREF, when echocardiography is not immediately available or in patients with mid-range left ventricular function.
There is high variability in the prevalence of ECG abnormalities among the included studies. This is likely to reflect different populations with different characteristics. There may well be substantial differences between, for example, inpatient and outpatient cohorts, Only two studies specifically discussed patients with HeFmrEF (LVEF 40%-49%). The data we have found cannot fully address the subject of ECG changes in HeFmrEF, particularly given the different boundary definitions of LVEF in the studies we found. In one study comparing patients across the three ejection fraction groups, QRS duration as well as the prevalence of atrial fibrillation, and LBBB and RBBB were intermediate between those of patients with HeFNEF and HeFREF in patients with HeFmrEF.
Hypertension is the commonest cause of HeFNEF. LVH is one of the diagnostic criteria for HeFNEF (Ponikowski et al., 2016a) and is associated with worse outcomes (Zile et al., 2011) . Electrocardiographic LVH is a strong predictor of diastolic dysfunction and treatment of hypertension results in regression of electrocardiographic LVH (Krepp, Lin, Min, Devereux, & Okin, 2014) . In an analysis of the I-PRESERVE trial, LVH was present in 59% of patients with HeFNEF using echocardiographic criteria and 28% using ECG criteria (Zile et al., 2011) .
The overall prevalence of electrocardiographic LVH in patients with
HeFNEF included in this review was 10%-30%.
Right ventricular systolic dysfunction as a consequence of increased pulmonary artery pressure is common in HeFNEF. It is present in at least one-fifth of patients with HeFNEF and is associated with worse prognosis (Gorter et al., 2018; Martinez Santos et al., 2016) . Right heart failure is a common mode of death in patients with HeFNEF (Aschauer et al., 2017) . 9% of patients with
HeFNEF have RBBB and a proportion of these patients may have lung disease and/or right heart failure contributing to their symptoms, consistent with phenogroup 2 features (Shah et al., 2015) .
The prevalence of COPD/lung disease in the studies included in this review was 12%-40%.
Left atrial enlargement is one of the hallmarks of HeFNEF (Ponikowski et al., 2016a) and is associated with atrial fibrillation and worse outcomes (Zile et al., 2011) . Only two studies have reported electrocardiographic P-wave duration in patients with HeFNEF. PR interval duration is prolonged in patients with HeFNEF compared to patients without heart failure, which may at least partly reflect atrial enlargement. In the absence of symptoms, an abnormal P-wave axis is independently associated with future HeFNEF (O'Neal et al., 2017) .
Clinical variables known to be associated with worse all-cause mortality in HeFNEF include older age and the presence of renal impairment, lower blood pressure, anemia, history of stroke, or dementia (Nikolaidou et al., 2017; Yap et al., 2015) . Our analysis shows that QRS duration ≥ 120 ms is a risk factor associated with worse outcomes in patients with HeFNEF.
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HeFNEF: LVEF ≥ 55%
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